IL285369B2 - Connexin 43 antibodies and their use - Google Patents

Connexin 43 antibodies and their use

Info

Publication number
IL285369B2
IL285369B2 IL285369A IL28536921A IL285369B2 IL 285369 B2 IL285369 B2 IL 285369B2 IL 285369 A IL285369 A IL 285369A IL 28536921 A IL28536921 A IL 28536921A IL 285369 B2 IL285369 B2 IL 285369B2
Authority
IL
Israel
Prior art keywords
antibody
antibodies
binding
seq
fragment
Prior art date
Application number
IL285369A
Other languages
English (en)
Hebrew (he)
Other versions
IL285369A (en
IL285369B1 (en
Original Assignee
Alamab Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alamab Therapeutics Inc filed Critical Alamab Therapeutics Inc
Publication of IL285369A publication Critical patent/IL285369A/en
Publication of IL285369B1 publication Critical patent/IL285369B1/en
Publication of IL285369B2 publication Critical patent/IL285369B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Computer And Data Communications (AREA)
IL285369A 2019-02-04 2020-02-04 Connexin 43 antibodies and their use IL285369B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962800869P 2019-02-04 2019-02-04
PCT/US2020/016606 WO2020163353A1 (en) 2019-02-04 2020-02-04 Connexin 43 antibodies and use thereof

Publications (3)

Publication Number Publication Date
IL285369A IL285369A (en) 2021-09-30
IL285369B1 IL285369B1 (en) 2025-06-01
IL285369B2 true IL285369B2 (en) 2025-10-01

Family

ID=71947290

Family Applications (2)

Application Number Title Priority Date Filing Date
IL285369A IL285369B2 (en) 2019-02-04 2020-02-04 Connexin 43 antibodies and their use
IL320816A IL320816A (en) 2019-02-04 2020-02-04 Connexin 43 antibodies and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL320816A IL320816A (en) 2019-02-04 2020-02-04 Connexin 43 antibodies and use thereof

Country Status (9)

Country Link
US (2) US12187794B2 (https=)
EP (1) EP3920969A4 (https=)
JP (2) JP7709917B2 (https=)
KR (1) KR20210153039A (https=)
CN (2) CN119700967A (https=)
AU (3) AU2020219112A1 (https=)
CA (1) CA3128987A1 (https=)
IL (2) IL285369B2 (https=)
WO (1) WO2020163353A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12227561B2 (en) 2018-04-02 2025-02-18 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
JP2023537316A (ja) * 2020-07-31 2023-08-31 アラマブ セラピューティクス， インコーポレイテッド 抗コネキシン抗体製剤
US20250002569A1 (en) * 2023-06-30 2025-01-02 Alamab Therapeutics, Inc. Method of treating osteoarthritis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015027120A1 (en) * 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
WO2017147561A1 (en) * 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP3960855A1 (en) 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
US6745478B2 (en) 2002-07-18 2004-06-08 Delillo Dominick D. Multi-purpose work knife
KR101225299B1 (ko) 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
DK1959981T3 (da) 2005-02-03 2020-01-27 Coda Therapeutics Ltd Anti-connexin 43 forbindelser til behandling af kroniske sår
MX2010012324A (es) 2008-05-15 2011-01-14 Biogen Idec Inc Anticuerpos anti-fn14 y usos de los mismos.
US20110223204A1 (en) 2008-06-04 2011-09-15 Bradford J Duft Treatment of pain with gap junction modulation compounds
CN103429732B (zh) 2010-12-27 2015-09-16 Lsip基金运营联合公司 iPS细胞及其制造方法
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
US12227561B2 (en) 2018-04-02 2025-02-18 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
JP2023537316A (ja) * 2020-07-31 2023-08-31 アラマブ セラピューティクス， インコーポレイテッド 抗コネキシン抗体製剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015027120A1 (en) * 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
WO2017147561A1 (en) * 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
AU2022218583A1 (en) 2022-10-06
KR20210153039A (ko) 2021-12-16
CN119700967A (zh) 2025-03-28
EP3920969A4 (en) 2022-11-30
US20220411494A1 (en) 2022-12-29
IL320816A (en) 2025-07-01
AU2020219112A1 (en) 2021-08-26
CA3128987A1 (en) 2020-08-13
CN112384244B (zh) 2025-01-24
AU2026201299A1 (en) 2026-03-12
US20250230233A1 (en) 2025-07-17
JP7709917B2 (ja) 2025-07-17
AU2022218583B9 (en) 2025-12-04
IL285369A (en) 2021-09-30
EP3920969A1 (en) 2021-12-15
US12187794B2 (en) 2025-01-07
JP2025090679A (ja) 2025-06-17
JP2022519293A (ja) 2022-03-22
IL285369B1 (en) 2025-06-01
WO2020163353A1 (en) 2020-08-13
CN112384244A (zh) 2021-02-19

Similar Documents

Publication Publication Date Title
JP7829605B2 (ja) コネキシン４３抗体およびその使用
US20250230233A1 (en) Connexin 43 antibodies and use thereof
CN111704672B (zh) 抗血浆激肽释放酶抗体
KR20160138220A (ko) 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
RS57413B1 (sr) Antitela za ligande bradikinin b1 receptora
HK40043616A (en) Connexin 43 antibodies and use thereof
CN113842456B (zh) 一种抗人4-1bb的单克隆抗体制剂及其用途
HK40043616B (zh) 连接蛋白43抗体及其用途
HK40100613A (zh) 连接蛋白43抗体及其用途
HK40042791A (en) Connexin 43 antibodies and use thereof
HK40112846A (zh) 抗血浆激肽释放酶抗体
TW202515906A (zh) 治療中風之方法
NZ618046B2 (en) Fc RECEPTOR BINDING PROTEINS